2 Wall Street Analysts Think Vertex Pharmaceuticals Stock Can Soar Another 20% or More Over the Next 12 Months. Here's Why They're Right.

When examining Nike's (NYSE: NKE) stock chart today, it's impossible to ignore the distressing decline. Financial analysts and social media users have been harsh critics, and with good reason. The stock has plummeted around 48% over the past year and more than 40% year-to-date, hovering near levels last seen a decade ago. Major banks like Bank of America and JPMorgan have downgraded Nike, issuing negative price targets.

At first glance, the outlook appears bleak. However, a closer look at Nike's history reveals a resilient company that has weathered challenging cycles and continued to reward long-term shareholders.

Wall Street's recent concerns are not unfounded. Nike has projected near-term revenue declines, projecting a 2% to 4% drop in the current quarter and low-single-digit growth for the remainder of fiscal 2026. China's market, a significant revenue driver, is expected to contract roughly 20% in the quarter. JPMorgan recently downgraded Nike to Neutral and then Underweight, warning that the company's "Win Now" initiatives might squeeze margins before they can generate lasting benefits.